CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-09-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise | +329 | 1,044,310 | ||
| 2019-09-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Shares withheld for taxes | −145 | $3.18 | $461 | 1,044,165 |
| 2019-09-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise · Restricted Stock Units | −329 | 991 | ||
| 2019-09-30 | Kendall Keith J CEO and President | Option exercise | +329 | 662,806 | ||
| 2019-09-30 | Kendall Keith J CEO and President | Shares withheld for taxes | −150 | $3.18 | $477 | 662,656 |
| 2019-09-30 | Kendall Keith J CEO and President | Option exercise · Restricted Stock Units | −329 | 991 | ||
| 2019-09-18 | Marshall Ken W. SVP, Chief Commercial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +66,000 | 66,000 | ||
| 2019-08-31 | Kendall Keith J CEO and President | Option exercise | +14,572 | 669,153 | ||
| 2019-08-31 | Kendall Keith J CEO and President | Shares withheld for taxes | −6,676 | $3.80 | $25K | 662,477 |
| 2019-08-31 | Kendall Keith J CEO and President | Option exercise · Restricted Stock Units | −14,572 | 43,716 | ||
| 2019-08-31 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise | +14,572 | 1,050,441 | ||
| 2019-08-31 | Schobel Alexander Mark Chief Innovation/Tech Officer | Shares withheld for taxes | −6,460 | $3.80 | $25K | 1,043,981 |
| 2019-08-31 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise · Restricted Stock Units | −14,572 | 43,716 | ||
| 2019-08-27 | Barber Daniel SVP-Chief Operating Officer | Purchase | +2,000 | $3.99 | $8K | 101,959 |
| 2019-08-21 | Scibetta James S Director | Purchase | +900 | $3.81 | $3K | 31,635 |
| 2019-08-20 | Scibetta James S Director | Purchase | +11,310 | $3.80 | $43K | 30,735 |
| 2019-08-19 | Scibetta James S Director | Purchase | +10,761 | $3.77 | $41K | 19,425 |
| 2019-08-14 | Kendall Keith J CEO and President | Purchase | +1,000 | $3.70 | $4K | 653,581 |
| 2019-08-14 | Kendall Keith J CEO and President | Purchase | +1,000 | $3.65 | $4K | 654,581 |
| 2019-08-13 | Kendall Keith J CEO and President | Purchase | +1,000 | $4.05 | $4K | 652,581 |
Page 18 of 24 · 462 trades